Global Statistics

All countries
528,399,054
Confirmed
Updated on May 24, 2022 7:18 am
All countries
484,651,985
Recovered
Updated on May 24, 2022 7:18 am
All countries
6,302,077
Deaths
Updated on May 24, 2022 7:18 am
Tuesday, May 24, 2022

Global Statistics

All countries
528,399,054
Confirmed
Updated on May 24, 2022 7:18 am
All countries
484,651,985
Recovered
Updated on May 24, 2022 7:18 am
All countries
6,302,077
Deaths
Updated on May 24, 2022 7:18 am
Molderizer and Safe Shield

Seeking Covid Pills, Poor Nations Fear Repeat of AIDS Crisis

Coronavirus challenges in China increase spiritual fervor

China (MNN) — China’s “zero-COVID” policy is taking a heavy toll on civilians and the economy. Mental health challenges abound, and China’s unemployment...

San Francisco urges booster shots for kids 5-11

The coronavirus pandemic is “not over anywhere until it’s over everywhere,” the head of the World Health Organization says — and it’s “most...

Smallpox vaccines can protect against monkeypox, and U.S. has 100 million doses

When Covid-19 struck, humanity faced an out-of-control outbreak without vaccines or therapies. If it were a knife fight, we brought a crayon. The level...

US births rose last year but still less than before pandemic

NEW YORK (AP) — U.S. births bumped up last year, but the number of babies born was still lower than before the coronavirus...


The cost to UNICEF of Paxlovid — including Pfizer’s insistence that UNICEF keep how much it pays confidential — remains a sticking point, said Dr. Philippe Duneton, who runs the therapeutics arm of the W.H.O. consortium. In announcing its “strong recommendation” for Paxlovid, the W.H.O. took the highly unusual step of publicly scolding Pfizer for a “lack of transparency,” which makes it difficult to know which countries have the drug and what they are paying.

“We need to have better visibility in terms of price,” Dr. Duneton said.

Manufacturers often prefer that the details of their sales agreements be secret so as not to weaken their hand with other potential buyers. Pfizer’s chief executive, Albert Bourla, reported last week that Paxlovid had been a “key growth driver” for the company, which is using a “tiered pricing approach” in which low- and lower-middle-income countries will get Paxlovid at a not-for-profit price.

In response to an inquiry from The New York Times, Pfizer issued a statement saying that it was “deeply disappointed by the sentiment expressed by our partners,” adding, “We have in good faith heard and responded to many of their concerns.”

Both Pfizer and Merck have also taken steps to make inexpensive generic versions of their pills available, signing licensing agreements with the Medicines Patent Pool, which was created during the global AIDS crisis to bring drugs to low- and middle-income nations at low cost. It took years, and bitter fights between activists and companies, to reach such agreements for H.I.V. drugs.

But the agreements for Covid antivirals do not apply to many middle-income nations, including much of Latin America and parts of northern Africa and Asia. The result, experts say, is that both poor and rich nations will have access, but countries in the middle will have to negotiate with the companies — or force the drugmakers to turn over their intellectual property.

So far, 36 companies from 12 countries have signed up to make generic Paxlovid. Companies in India are already making generic versions of both Paxlovid and molnupiravir. The expectation is that both drugs will ultimately be available in about 100 low- and middle-income countries, covering about half the world’s population. The companies will not receive royalties from the sales while the W.H.O.’s declaration of the pandemic as a global health emergency remains in effect.

“Given the severity of the pandemic and given the fact that vaccines had a very uneven penetration rate, we felt that this was a very important contribution the company could make,” said Paul Schaper, executive director for global public policy at Merck.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Coronavirus challenges in China increase spiritual fervor

China (MNN) — China’s “zero-COVID” policy is taking a heavy toll on civilians and the economy. Mental health challenges abound, and China’s unemployment...

San Francisco urges booster shots for kids 5-11

The coronavirus pandemic is “not over anywhere until it’s over everywhere,” the head of the World Health Organization says — and it’s “most...

Smallpox vaccines can protect against monkeypox, and U.S. has 100 million doses

When Covid-19 struck, humanity faced an out-of-control outbreak without vaccines or therapies. If it were a knife fight, we brought a crayon. The level...

Related Articles

Coronavirus challenges in China increase spiritual fervor

China (MNN) — China’s “zero-COVID” policy is taking a heavy toll on civilians and the economy. Mental health challenges abound, and China’s unemployment...

San Francisco urges booster shots for kids 5-11

The coronavirus pandemic is “not over anywhere until it’s over everywhere,” the head of the World Health Organization says — and it’s “most...

Smallpox vaccines can protect against monkeypox, and U.S. has 100 million doses

When Covid-19 struck, humanity faced an out-of-control outbreak without vaccines or therapies. If it were a knife fight, we brought a crayon. The level...